Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX versus SODIUM HEPARIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX versus SODIUM HEPARIN.
ANGIOMAX vs SODIUM HEPARIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates, thereby inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
Binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby preventing fibrin formation and extension of thrombi.
1 mg/kg intravenous bolus followed by 0.1 mg/kg/hour continuous intravenous infusion for duration of procedure; alternatively, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg/hour continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention.
Initial IV bolus 80 units/kg followed by continuous IV infusion at 18 units/kg/hour; adjusted based on aPTT. Alternatively, subcutaneous: 333 units/kg loading dose then 250 units/kg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 25-30 minutes in patients with normal renal function; increased to 2-3 hours in dialysis-dependent patients
Terminal elimination half-life is dose-dependent: 0.5-1.5 hours at low doses, 1.5-2.5 hours at high doses. Clinically, anticoagulant effect half-life is approximately 1-5 hours, with shorter half-life at lower doses.
Renal: ~90% unchanged; biliary/fecal: negligible (<1%)
Renal: negligible; primarily cleared by hepatic and reticuloendothelial system (desulfation and depolymerization). Unchanged drug not excreted in urine.
Category C
Category A/B
Anticoagulant
Anticoagulant